In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts on the biopharmaceutical marketplace and patient care. Specifically, PhRMA noted two significant areas of concern for the Administration to consider.
- It could lead to patients paying more out of pocket for medicines through changes related to patient assistance programs. As noted in PhRMA’s comments, “Patient assistance programs provide an important source of financial support for eligible patients and can improve patient adherence, leading to improved patient outcomes.” Unfortunately, CMS is proposing to make it more difficult for manufacturers to offer assistance, despite the positive impact that this assistance can have on patients and their health. “If finalized, these changes could potentially reduce the availability of patient assistance, which could, in turn, inhibit the ability of patients to pay their out-of-pocket costs. As a result, these proposed changes could lead to patient abandonment of necessary therapies and could worsen health outcomes.”
- It risks impeding progress in patient care through its proposed revised definition of a “line extension.” As explained in PhRMA’s comments, “The [Medicaid] statute expressly delineates the bounds of a ‘line extension’: product alterations similar to changing an immediate release drug to an extended release formulation. Congress passed this narrow definition to target ‘slight’ changes in drugs, such as changes in color … .” Yet CMS is proposing a new definition that would sweep in many categories of innovative medicines not just those medicines with “slight” changes, subjecting them to higher Medicaid rebates. “If finalized, the proposal would create serious financial penalties for manufacturers seeking to improve their products based on continually evolving research and science and risks impeding progress in patient care at a time when pharmaceutical innovation is more important than ever.” Now is not the time for policies that could discourage continued investment in research and development of innovative medicines.
At the same time, PhRMA also recognized some of the other pieces of the proposed rule as potential steps in the right direction. For example, the Administration’s continued efforts to help support market-based solutions, such as value-based arrangements (also called value-based contracts), are greatly appreciated. At the same time, PhRMA’s comments highlighted one aspect of the value-based arrangements proposal that was particularly unclear – the proposal for “multiple best prices.” Having identified a number of key policy and operational questions that need to be addressed, PhRMA asked CMS to issue a revised proposed rule on this concept.
The proposed rule includes a number of complex changes with significant implications for patient care. Despite this, the Administration crammed all these changes together in one rule with an extremely short review period – diminishing the importance of taking the time to ensure these changes are in the best interest of patients. Rather than rushing to advance such far-reaching policies, CMS should fully consider the impacts these changes could have and carefully review the comments submitted by all of the stakeholders before moving forward.
For more information, read our full comments here.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Delivering breakthroughs and lower costs for patients
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Ensuring access to affordable medicines for patients through Medicaid
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
Tactic to exploit patient assistance likely to increase despite harm to patients
Medicaid by the numbers
Providing affordable access to medicines in Medicaid
Increased use of prior authorization in Medicaid is blocking access for patients
Incomplete evaluations undermine patient access to transformational medicine
Manufacturers provided $42 billion in Medicaid discounts in 2021 alone
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
States can support access to medicine as COVID-19 Public Health Emergency ends
Study finds hepatitis C cure saved Medicaid $15 billion
Putting Delaware patients first: Protecting Patient Assistance Programs
Busting 3 Myths About Copay Coupons
Making coupons count for patients with HIV
Copay assistance is a lifeline for patients. So why are insurers blocking it?
Innovative contracts continue to gain traction and improve quality of care
Medicaid 101: Three charts on access and spending
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Insurers shift medicine costs to patients with severe chronic illnesses
Tennessee’s Medicaid demonstration fails patients
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Recent administration actions undermine patient assistance programs
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
PPA celebrates 13 years of helping patients access their medicines
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Clarity around anti-kickback statute needed to promote innovative payment arrangements
New report shows better diabetes management saves money and improves patient outcomes
Medicare Monday: How Part B has evolved over the years
12 years of the Partnership of Prescription Assistance
PPA: 2016 in review
PhRMA submits comments to CMS on Medicaid proposed rule
Patient Assistance Programs
Medicaid
Value-Based Contracting
PhRMA submits comments to CMS on Medicaid proposed rule
PhRMA submits comments to CMS on Medicaid proposed rule